Literature DB >> 23424051

Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease.

Scott Ayton1, Peng Lei, James A Duce, Bruce X W Wong, Amelia Sedjahtera, Paul A Adlard, Ashley I Bush, David I Finkelstein.   

Abstract

Ceruloplasmin is an iron-export ferroxidase that is abundant in plasma and also expressed in glia. We found a ∼80% loss of ceruloplasmin ferroxidase activity in the substantia nigra of idiopathic Parkinson disease (PD) cases, which could contribute to the pro-oxidant iron accumulation that characterizes the pathology. Consistent with a role for ceruloplasmin in PD etiopathogenesis, ceruloplasmin knockout mice developed parkinsonism that was rescued by iron chelation. Additionally, peripheral infusion of ceruloplasmin attenuated neurodegeneration and nigral iron elevation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model for PD. These findings show, in principle, that intravenous ceruloplasmin may have therapeutic potential in PD.
Copyright © 2013 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23424051     DOI: 10.1002/ana.23817

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  81 in total

Review 1.  Treating Alzheimer's disease by targeting iron.

Authors:  Sara Nikseresht; Ashley I Bush; Scott Ayton
Journal:  Br J Pharmacol       Date:  2019-02-11       Impact factor: 8.739

Review 2.  Metals in Alzheimer's and Parkinson's Disease: Relevance to Dementia with Lewy Bodies.

Authors:  Erin J McAllum; David I Finkelstein
Journal:  J Mol Neurosci       Date:  2016-08-08       Impact factor: 3.444

3.  Prognostic value of elevated serum ceruloplasmin levels in patients with heart failure.

Authors:  Muhammad Hammadah; Yiying Fan; Yuping Wu; Stanley L Hazen; W H Wilson Tang
Journal:  J Card Fail       Date:  2014-08-13       Impact factor: 5.712

Review 4.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

5.  Single-nucleotide polymorphisms and haplotypes of non-coding area in the CP gene are correlated with Parkinson's disease.

Authors:  Na Zhao; Jianqiu Xiao; Zhiyong Zheng; Guoqiang Fei; Feng Zhang; Lirong Jin; Chunjiu Zhong
Journal:  Neurosci Bull       Date:  2015-03-10       Impact factor: 5.203

6.  Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain.

Authors:  Sian Genoud; Blaine R Roberts; Adam P Gunn; Glenda M Halliday; Simon J G Lewis; Helen J Ball; Dominic J Hare; Kay L Double
Journal:  Metallomics       Date:  2017-10-18       Impact factor: 4.526

Review 7.  Interrogating Parkinson's disease associated redox targets: Potential application of CRISPR editing.

Authors:  M A Artyukhova; Y Y Tyurina; C T Chu; T M Zharikova; H Bayır; V E Kagan; P S Timashev
Journal:  Free Radic Biol Med       Date:  2019-06-12       Impact factor: 7.376

Review 8.  Iron and Neurodegeneration: Is Ferritinophagy the Link?

Authors:  Giorgio Biasiotto; Diego Di Lorenzo; Silvana Archetti; Isabella Zanella
Journal:  Mol Neurobiol       Date:  2015-10-14       Impact factor: 5.590

9.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

10.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.